38 results about "Aminoglycoside Drugs" patented technology

The invention discloses a measuring method for detecting residual quantities of streptomycin, dihydrostreptomycin, kanamycin, spectinomycin and neomycin in food simultaneously. The method comprises steps as follows: (1) extraction; (2) purification; (3) preparation of a matrix standard working solution; (4) measurement with LC-MS / MS (liquid chromatography-tandem mass spectrometry). The method has the advantages of simplicity in operation, accuracy, high sensitivity and good repeatability, can completely meet technical requirements for corresponding product security detection in China, the European Union, America and Japan and can provide powerful technical support for guaranteeing food security of people in China and sound development of export trades.

The invention relates to the field of gene detection, and particularly relates to a kit and method for detecting an aminoglycoside drug-induced deafness-sensitive gene through a fluorescent PCR (polymerase chain reaction)-melting curve method. The technical scheme of the invention provides a kit for detecting an aminoglycoside drug-induced deafness-sensitive gene. The kit comprises a PCR solution, a negative quality control sample and a positive quality control sample, wherein the PCR solution comprises primers, a PCR Buffer, a dNTP (deoxyribonucleotide triphosphate) mixed solution, saturated fluorescent dyes, a Taq enzyme and a UNG enzyme. In the invention, the specific PCR primers are designed according to SNP (single nucleotide polymorphism) sites of the aminoglycoside drug-induced deafness-sensitive gene, two aminoglycoside drug-induced deafness-sensitive sites can be detected in one PCR, the operation can be finished in one tube, and the detection is quick, accurate and wide in range.

The invention discloses an aminoglycosides molecular molecularly imprinted solid-phase extraction column. Molecularly imprinted polymeric microspheres are filled in a columnar shell, and a preparation method for the molecularly imprinted polymeric microspheres comprises the steps of: taking 3-aminopropyltriethoxysilane or phenyltriethoxysilane as functional monomers, taking tetraethyl orthosilicate as a cross-linking agent and taking aminoglycoside antibiotics as template molecules, performing hydrolytic condensation by adopting a sol-gel method, forming a rigid network structure of an Si-O-Si bond on the surface of activated silica gel to form the polymeric microspheres; and eluting.by using template molecules, so as to obtain the molecularly imprinted polymeric microspheres. The extraction column is used for separating and concentrating target objects before sample pretreatment is performed on residue of veterinary drugs of the aminoglycoside antibiotics, and selectively adsorbing the target objects, and has the advantages of being simple and fast in separation, purification and concentration, little in organic solvent consumption and high in repeatedly used times, and the like.

The invention discloses primers and a kit for detecting the aminoglycoside drug-resistance genes of bacteria, and belongs to the technical field of microbiological detection. The sequences of the primers provided by the invention are shown in SEQ ID NO: 1-10, and by comparing the aminoglycoside drug-resistance gene sequence of multiple bacteria and clinic isolated strains in the gene sequence library of NCBI, the specific primers designed at conserved sites are capable of rapidly detecting the five aminoglycoside drug-resistance genes of aac(3)-II, aac(6')-Ib, aph(3')-III, ant(3')-1a and ant(4')-1a5 of multiple bacteria. The invention further discloses a kit containing the primers and used for detecting the aminoglycoside drug-resistance genes of bacteria, wherein the kit is capable of rapidly and accurately detecting the aminoglycoside antibiotic-related drug-resistance genes of bacteria.

The invention relates to the field of gene detection, in particular to a kit and a primer pair group for detecting drug-induced deafness susceptibility gene mutation sites, wherein the kit and the primer pair group can be used for detecting aminoglycoside drug susceptibility genes in mitochondria. A specific primer amplification and real-time fluorescence PCR technology is adopted, a new primer pair group is designed aiming at mutant nucleic acid to be detected, the primer is extended to product a specific PCR product when the mutant nucleic acid exists, a fluorescent substance is added into each reaction system, the fluorescent substance is bonded to the PCR product after amplification is completed, the produced melting peak is analyzed by adopting a melting curve, whether a corresponding mutant type exists on the nucleic acid or not is judged through the existence of the specific melting peak, and the specificity is high; the detection of two mutation sites can be completed by using a single tube and a single channel only, the requirements on instruments are low and the operation is simple to perform.

The invention belongs to the field of analytical chemistry and relates to a pretreatment method for detecting aminoglycoside antibiotic residues in milk. The method comprises the following steps: synthesizing a boric acid modified mesoporous magnetic graphene composite material, carrying out two-step post synthesis grafting reactions, carrying out a reaction between APB and GLYMO to obtain GLYMO-APB, and grafting GLYMO-APB onto the surface of the mesoporous magnetic graphene composite material to obtain the boric acid modified mesoporous magnetic graphene composite material. A boric acid functional group modified on the mesoporous inner wall of the composite material can be selectively combined with an aminoglycoside drug in milk through interaction between boric acid and vicinal diol structure of glycoside micromolecules, and interference of biomacromolecules such as fat, protein and the like in a milk matrix is eliminated. According to the method, antibiotic residues in milk are enriched by the utilization of specific boric acid-aminoglycoside effect, and problems such as high time consumption, poor selectivity, severe matrix interference and the like are overcome.

The invention provides a composition comprising an effective dose of etimicin or a pharmaceutically acceptable salt thereof, an anti-inflammatorily effective dose of steroids or non-steroid anti-inflammatory drugs, and an effective dose of a water-retaining or wetting agent or anti-xerophthalmia drug, and application of the composition to preparation of external drugs for local administration of the eyes, the nose or skin and for prevention and treatment of conjunctivitis in human beings or mammals, angular blepharitis, keratitis, scleritis, trachoma, xerophthalmia, cataract, otitis externa, otitis media, folliculitis, furuncle, pustule and the like. The composition provided by the invention has better curative effect or treatment compliance.

The invention provides a method for determining an aminoglycoside drug in an animal muscle tissue without using of an ion pair reagent, and belongs to the technical field of veterinary drug residue detection, and the method comprises performing liquid chromatography-tandem mass spectrometry detection on an injection sample, and obtaining the content of the aminoglycoside drug in the injection sample according to a standard curve of the content of the aminoglycoside drug and a liquid chromatogram of the injection sample; wherein a liquid chromatography column is SIELC Obelisc R. The method provided by the invention can enhance the chromatographic retention without using of the ion pair reagent, and can detect the content of the aminoglycoside drug the animal muscle tissue, the detection limit and the limit quantification of the drug are respectively in a range of 1 to 10 mu g / kg and a range of 2-20 mu g / kg; within-run precision and between-run precision are 2-14.4% and 3.7-19.8% respectively.

A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass median aerodynamic diameter predominantly between 1 to 5μ, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.

The invention discloses a chemical medicine composition for treating helicobacter pylori (Hp) infection of adults through oral administration. The composition at least comprises fosfomycin or pharmaceutical salts such as a sodium salt, a calcium salt, fosfomycin trometamol and aminoglycoside medicines of the fosfomycin of a common dosage of an adult, and the aminoglycoside medicines are selected from tobramycin, netilmicin, etimicin, isepamicin, amikacin and common salts such as sulfate, of the medicines.

The invention relates to a method for synthesizing artificial antigen having aminoglycoside medicine multi-antigen determinant, belonging to the biochemical engineering technical field. The method uses neomycin, kanamycin and gentamicin as hapten, uses a carbodiimide method to couple the hapten with protein bovine serum protein BSA as a carrier, and uses a gel electrophoresis method to measure the coupling ratio of coupled matter. The method successfully synthesizes the artificial antigen having the aminoglycoside medicine multi-antigen determinant, is simple and effective in synthesis method, can be used in immune analysis completely, provides the necessary artificial antigen for after research of people, and can meet the needs of the research on the aminoglycoside medicine in China.

The invention relates to a method for detecting aminoglycosides in milk, which comprises the following steps: (1) extracting; (2) preparing a standard working solution; (3) performing determination bya high performance liquid chromatography-tandem mass spectrometry (HPLC-MS / MS), wherein the aminoglycosides are paromomycin, tobramycin, gentamicin, kanamycin, amikacin, apramycin, streptomycin, dihydrostreptomycin, neomycin, spectinomycin and hygromycin B. An MIP solid phase extraction column is uses in the step of extracting, thereby simplifying the pretreatment step, reducing the consumption of reagents and the time uses for the pretreatment; a SiELC Obelisc R chromatographic column is used for the separation of 11 kinds of aminoglycosides; and the mobile phase does not require heptafluorobutyric acid and does not contaminate the mass spectrometry.

The invention relates to a method for testing aminoglycoside drug residue in animal derived food. The method comprises the steps of extracting the residual aminoglycoside in a sample by phosphate buffer solution, performing enrichment purification on SupelMIP SPE-Aminoglycosides solid-phase extraction column, separating an SIELC ObeliscR chromatographic column and Hypercarb chromatographic column,and performing measuring according to a high-efficiency liquid chromatograph-tandem mass spectrometry. The method for testing aminoglycoside drug residue in the animal derived food can simultaneouslydetect the residue condition of 16 aminoglycosides in the animal derived food. Compared with reversed phase chromatography for analyzing the drug, the method according to the invention has advantagesof no adding of ion pairing agent in a testing process, and no pollution of a mass spectrometer. Compared with hydrophilic interaction chromatography, the method according to the invention has advantages of high sensitivity, high peak form, high response speed and large number of kinds of analyzing drugs.

The invention provides an antibacterial nanomaterial, and a preparation method and application thereof. The antibacterial nanomaterial is aminophenol modified gold nanoparticles, and aminophenol is modified on the surfaces of the gold nanoparticles through gold-ammonia bonds. The aminophenol is combined with the gold nanoparticles, then hydroxyl groups on the surface of the obtained antibacterialnanomaterial can target polysaccharides on the surface of bacteria, permeability of cell membranes is improved by destroying cell walls of the bacteria, aminophenol serves as a functional group to becombined with 16S ribosome RNA of the bacteria, protein synthesis is inhibited, then the bacteria are killed, and a good antibacterial effect is achieved. Meanwhile, the surface of the antibacterial nanomaterial is negatively charged, so that the antibacterial nanomaterial has excellent biocompatibility, does not induce bacteria to generate drug resistance, and has higher biological safety compared with renal toxicity drugs such as aminoglycoside drugs and the like.

The invention provides a composition for improving the absorbance of aminoglycoside drug, which has greatly-improved absorbance in organisms and exhibits effective pharmacological action. The composition contains 0.1 to 5% absorption enhancer, which is one or more of medium chain sodium aliphatate salt and cholic acid salts; 5 to 20% of aminoglycoside drug, and the balance of pharmaceutically acceptable auxiliaries. Oral administration of the aminoglycoside drug results in quite little absorption of the aminoglycoside drug, and clinical oral drug is used only as the drug for enteric infection. According to the invention, as the absorption enhancer is added, the applicable scope of the aminoglycoside drug is widened, and oral administration can reach the purpose of treating general infection.

The invention provides a nucleotide acid fragment composition related to mycobacterium tuberculosis drug resistance detection of four second-line drugs, namely a fluoroquinolone drug, aminoglycoside drug kanamycin and amikacin (amikacin) and cyclopeptide drug capreomycin which are used for treating tuberculosis, and application thereof, and particularly provides a promotor mutation nucleotide acid fragment composition of a drug-resistant related gene gyrA of the fluoroquinolone drug and drug-resistant related genes rrs and eis of the aminoglycoside drug kanamycin and amikacin (amikacin) and the cyclopeptide drug capreomycin, a specific mutation detection oligonucleotide probe, a kit prepared through the specific mutation detection oligonucleotide probe and a related drug resistance detection method.

The present invention specifically discloses a compound quinolone injection for livestock, and a preparation method thereof. The compound quinolone injection for livestock comprises an active component and a solvent, wherein the active component comprises the following components, by mass volume concentration, 1-30% of a quinolone drug, 2-20% of an aminoglycoside drug, 0.2-5% of vitamin C, 1-8% of taurine, 2-10% of a co-solvent, 0.1% of an antioxidant, and 0.01% of EDTA-2Na, and the solvent is water for injection. The preparation method comprises: dissolving the components, adopting a hydrochloric acid solution to adjust the pH value to 3.5-5.5, filtering with a filter membrane, carrying out sub-package, and carrying out flowing steam sterilization. According to the injection of the present invention, gram-positive bacteria infections and gram-negative bacteria infections or mixing infections of bacterial and mycoplasma in the livestock can be treated, the injection is easy to use in clinic, and rapid animal disease rehabilitation is easily achieved.

The invention discloses a method for detecting aminoglycoside drug residues in animal-derived food. The method comprises the following steps: (1) preparing an aminoglycoside standard solution, and selecting a matrix for standard preparation; and (2) extracting and purifying a sample to be detected, and detecting the sample to be detected by adopting liquid chromatography-tandem mass spectrometry to obtain the residual quantity of the aminoglycoside drugs in the animal-derived food. According to the method for detecting aminoglycoside drug residues in animal-derived food, an ionization reagentis not used, aminoglycoside drug detection of multiple matrixes can be met at the same time, and the problems of pollution and ion inhibition of heptafluorobutyric acid ions to reagents and instruments can be well avoided.

The invention discloses a primer and kit for detecting aminoglycoside drug resistance genes of aeromonas hydrophila, and belongs to the technical field of microorganism detection. The sequence of the primer is shown as SEQ ID:1-4, and the aminoglycoside drug resistance genes such as aac(6')-Iz and aph of the aeromonas hydrophila can be quickly detected by searching an aeromonas hydrophila ATCC7966 strain gene sequence library of the NCBI for a aminoglycoside drug resistance gene and designing the specific primer. The invention further discloses the kit which contains the primer and is used for detecting the aminoglycoside drug resistance genes of the aeromonas hydrophila, and therefore the related drug resistance genes of aeromonas hydrophila aminoglycoside antibiotics can be quickly and accurately detected in a laboratory.

The invention discloses application of deferiprone in inhibition of ototoxicity of aminoglycoside drugs, and belongs to the field of drug-induced deafness. The invention discloses an application of deferiprone (DFP) in protection of hearing loss caused by aminoglycoside drugs. The DFP is the only oral active iron chelating agent and is clinically used for treating blood transfusion iron overload in thalassemia. According to the application, aminoglycoside drug damage, hair-like cells HEI-OC1 and mitochondrial autophagy occurrence levels in in-vitro cultured cochlea tissues are firstly researched, the protective effect of the DFP on the hair cells by regulating mitochondrial autophagy on the in-vitro cultured cochlea tissues is researched, and finally, the protective effect of the DFP on mouse hearing loss caused by aminoglycoside drugs is researched. A new thought is provided for treating drug-induced deafness, and a new target is provided for clinically helping a patient to recover and reconstruct an auditory function.

The invention relates to a method for synthesizing general artificial antigen of aminoglycoside medicine, belonging to the biochemical engineering technical field. The method uses neamine as hapten, uses a glutaraldehyde method to couple the neamine with protein BSA as a carrier, and uses a gel electrophoresis method to measure the coupling ratio of coupled matter. The method successfully synthesizes the artificial antigen of neamine, is simple and effective in synthesis method, can be used in immune analysis completely, provides the necessary artificial antigen for after research of people, and can meet the needs of the research on the aminoglycoside medicine in China.

The invention relates to a high-efficiency and broad-spectrum compound antibacterial drug composition for livestock and poultry, wherein every 100 parts by weight of the pharmaceutical composition contains 1-30 parts by weight of florfenicol and 1-30 parts by weight of drugs selected from aminoglycosides of antibacterial agents. The florfenicol and aminoglycoside pharmaceutical composition of the present invention has synergistic antibacterial effect, and enhances the effect of preventing and treating respiratory diseases and digestive tract diseases of livestock and poultry. The pharmaceutical composition of the present invention can be in the form of premix, oral liquid and injection, and can also be added to feed. The invention provides a compound preparation with high efficiency and wide antibacterial spectrum.

The invention relates to an aminoglycosides related 12s rRNA gene mutation site detection kit, in particular to a detection primer composition, a kit and a method for an aminoglycosides related 2s rRNA gene polymorphism mutation site. The primer composition comprises polymorphism detection primers and internal control gene detection primers, wherein sequences of the polymorphism detection primersare as follows: a first polymorphism primer: 5'-TACGCATTTA TATAGAGGATA-3'; a second polymorphism primer: 5'-TACGCATTTA TATAGAGGACG-3'; a third polymorphism primer: 5'-GTGCACTTGG ACGAACCAGA-3'; a fourth polymorphism primer: 5'-GCGTACACAC CGCCCGTCAAC-3'; a fifth polymorphism primer: 5'-GCGTACACAC CGCCCGTCAGT-3'; a sixth polymorphism primer: 5'-TAAATGCGTA GGGGTTTTAG-3'; sequences of the internal control gene detection primers are as follows: a first internal control primer: 5'-AGCAAGCAGG AGTATGACG-3'; a second internal control primer: 5'-GAAAGGGTGT AACGCAACT-3'. Compared to the prior art, the aminoglycosides related 12s rRNA gene mutation site detection kit has the advantages of high sensitivity, high specificity, short time consumption and the like in the process of detecting 12s rRNA gene mutation.

The present invention provides a method of attenuating side effects caused by aminoglycosides by administering aminoguanidine either before or during the treatment with the aminoglycoside. The invention also provides compositions and kits for use in the treatment of infections that use aminoglycosides that can cause side effects such as nephrotoxicity and ototoxicity.

The invention discloses application of magnesium isoglycyrrhizinate (MgIG) to the preparation of a medicine for lowering the ototoxicity caused by aminoglycoside antibiotics, and relates to the fieldof natural medicines. A rat ototoxicity model caused by an aminoglycoside antibiotic gentamicin (GM) and amikacin (AMK) is established; discovering that by jointly using the MgIG, the MgIG can be usedfor effectively ameliorating the threshold value increment of the auditory brainstem response (ABR) caused by the aminoglycoside antibiotisc, and meanwhile, is used for lowering the concentration ofan aminoglycoside medicine in the tissue of an inner ear of a rat and reversing the dysfunction, which is caused by the medicine, of a mitochondrion in the tissue of the inner ear, and the MgIG in theapplication provided by the invention can be used cooperatively to antagonize the ototoxicity caused by the aminoglycoside antibiotics.